British drugmaker GSK said on Tuesday (December 7) its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.
Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike
protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.
"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK chief scientific officer Hal Barron said.
New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a
standalone prescription medicine and vaccine business since carving out its consumer health division Haleon.
After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of
strong results.
The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy.
Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain
around U.S. litigation over heartburn drug Zantac.
Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.
England is set to reopen temporary field hospitals to contain a possible overspill of inpatients due to a surge in coronavirus cases, the national health service said Thursday.
Fuelled by the highly contagious Omicron variant, daily cases have ballooned, standing at more than 183,000 on Wednesday.
NHS England said it would start building the structures in the grounds of eight hospitals in cities including London, Bristol and Leeds from this week, with each
designed to house around 100 extra patients.
"Given the high level of Covid-19 infections and increasing hospital admissions, the NHS is now on a war footing," National medical director Stephen Powis said.
The extra beds are designed for patients who are recovering from illnesses, including those who no longer have Covid, to free up space and staff to treat large numbers of virus cases.
American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022.
"We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call.
Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and
manufacturing problems.
Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.
Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market,
the German company's top executive Ugur Sahin told magazine Der Spiegel.
BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies
on and the locations where it will conduct the trials, Sahin said.
The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular
treatment for cancer patients.
"We believe that this should be possible for large amounts of patients before 2030," Sahin said.
GSK Consumer Healthcare has recently unveiled a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care.
The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and industry leaders to discuss the critical role of pharmacy in the age of self-care following the Covid-19 pandemic.
"We've seen Covid-19 have a significant impact on consumers' understanding of self-care, leading to an increased focus on wellbeing and everyday healthcare. During this time, pharmacies played a vital role in providing care and advice to their patients - particularly with many other health facilities closed. Our research shows that more than half of Europeans are planning to consult their pharmacist more often than before the pandemic. Yet in general, pharmacists remain under-utilised, despite being the most widely distributed health resource in Europe," said Tess Player, global head of expert at GSK Consumer Healthcare.
Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals.
Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic.
The honours were announced on Thursday (13).
Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019.
He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar
markets and spearheaded its operations in the US.
The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair.
DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly.
With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca.
She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services.
In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to
prepare for the proposed spin out of the company from its parent, Novartis, expected later this year.
She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of
the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing
the sustainability of our industry so we can continue to play our vital part in the health of the nation."
Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through
her role on the BGMA board and leadership of a key strategic committee.
Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list.
Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others.
"That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it.
Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK.
His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.
The Pharmacists' Defence Association (PDA) has raised the issue faced by the pharmacy students on returning to in-person assessments while urging the
universities to take an empathetic approach in transition of online to in-person exams.
It was highlighted by the association that many student members were apprehensive about the return to in-person assessments. This is due to their continuing worry of Covid-19 transmissions and anxiety caused by changing exam formats and procedures.
However, with the ease of Covid restrictions, now pharmacy schools are able to decide how exams are conducted but the PDA believes that they should communicate the
process to students in advance.
"A return to normal university life is considered to be beneficial to student health and well-being. In-person exams are an important part of preparing for students' future trainee assessment examinations, GPhC accreditation for pharmacy schools, and ensuring the integrity of exam results. As future healthcare professionals, face-to-face interaction is also an integral part of the role," said the PDA.
A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming
his community centre into vaccination hub during Covid-19 pandemic.
Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA,
Nick Knowles, who hosted the event.
At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population,
with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to
80,000 vaccinations being administered, the overall highest vaccination uptake in North West London.
Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better
choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge
and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with
their communities.
NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than
before the pandemic, revealed NHS.
Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the
pandemic.
"Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every
day over the last year," said NHS.
In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests,
mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease.
More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of
the biggest programme to improve early lung cancer diagnosis in health service history.
Polio has been detected in sewage samples in London, the first sign since the 1980s that the virus could be spreading in the UK, but no cases have been found,
authorities said.
The risk of infection from the disease, which causes paralysis in children in under one per cent of cases, was also low because of high vaccination rates, the UK
Health Security Agency (UKHSA) said.
The agency nevertheless encouraged parents to make sure their children were vaccinated after the discovery of the virus during routine wastewater surveillance -
particularly those who may have missed shots during the Covid-19 pandemic.
Nationwide vaccination levels are above the 90 per cent needed to prevent outbreaks, but London's coverage rates among the under-twos has dipped below that in recent
years.
NHS England will begin contacting parents of children under five who are not immunised.
Polio, spread mainly through contamination by faecal matter, used to kill and paralyse thousands of children annually worldwide. There is no cure, but vaccination
brought the world close to ending the wild, or naturally occurring, form of the disease.
In his maiden speech delivered to community pharmacy since becoming new minister with responsibility for the sector, Will Quince MP said he's determined to be
"your champion" and "voice in government".
Addressing delegates on Wednesday (Oct 12) as chief guest at the 22nd Pharmacy Business Awards in central London, he praised community pharmacy for delivering 25
million Covid-19 vaccines, five million flu jabs, 200 million lateral flow testing kits and millions of medicines throughout the pandemic.
"These local efforts became the national success story," he told over 600 attendees at a gala dinner held at the iconic Park Plaza Westminster Bridge hotel
overlooking the Houses of Parliament.
'We need you now'
Quince, who was appointed minister of state at the Department of Health and Social Care on 7 September 2022, added: "Just as we needed you in the pandemic, we
need you now," highlighting the vital role of community pharmacy in realising the secretary of state (Thérèse Coffey)'s vision, particularly in regard to her
much talked about 'Plan for Patients'.
The message of Diwali - a festival of new beginnings and the triumph of good over evil and light over darkness - seems to take on new layers of meaning every
year.
At the height of the Covid pandemic, it brought to mind the importance of togetherness, as we all struggled through lockdowns and missed the human contact that is
so important to us all.
In 2022, sadly, it feels like there's a lot of darkness in the world. Diwali is so full of hope for the future and we certainly need some of that that right now. In
troubled times, both in the UK and across the globe, Diwali provides an opportunity to reflect and hope for better times ahead.
In their own way, pharmacies bring light to the communities they serve - giving help and reassurance to many vulnerable people. As chair of the NPA it is truly a
privilege to support pharmacy teams to deliver this vital work all year round. Diwali is a family feast - at the NPA we like to think of ourselves as the family
of family-owned pharmacies.
he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair.
Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of
Medicine and Health Sciences, responsible for developing the clinical teaching at Keele.
Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education,
particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a
principal fellowship of the Higher Education Academy in November 2020.
Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of
retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.
The UK Health Security Agency (UKHSA) has published the latest national surveillance data on antibiotic prescribing and resistance.
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report showed an increase in antibiotic use in all settings
(apart from dental) in 2022.
According to the report, antibiotic prescribing rose by 8.4 per cent in 2022 compared with 2021, although the number remains below 2019 pre-pandemic levels.
"There are many reasons behind the increase in prescribing, one of which is likely related to decreased immunity and exposure to infections during the
COVID-19 pandemic that may have underpinned the increased transmission in co-circulating infections, namely: influenza (flu), respiratory syncytial virus
(RSV) and group A streptococcus (GAS)," the report stated.
Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83.
Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs
that could add at least $25 billion in annual sales by the end of the decade.
"The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric.
Biohaven forecast Nurtec sales of $825 million to $900 million in 2022.
Pfizer said it expects the pills to eventually overtake the shots.
AstraZeneca said its antibody cocktail against Covid-19 would - unlike its vaccine - be priced commercially as it negotiates supply contracts with governments around the globe.
"We are looking at a commercial pricing strategy. That is part of our negotiations with governments," Iskra Reic, Astra's executive vice president for vaccines and immune therapies, said in a media call on Thursday.
She added that the group's main objective was to make the shot affordable and broadly available.
Hobbs, who joined the company in 2019, navigated it through the challenges of the COVID-19 pandemic, and successfully oversaw the acquisition and integration
of Lexon in 2023. He will retire from the company at the end of September 2024.
"After five years with the company, I am retiring at the end of September to spend time with my wife who was diagnosed with motor neurone disease last year," Hobbs
said.
"I wish to extend my personal thanks to our owners, the Bestway Group, for their kindness and understanding of our situation.
"It has been a privilege to lead the Well Pharmacy, now Bestway Healthcare organisation. The business is resilient for today and fit to prosper in the long term.
When I leave it will be with gratitude and admiration for the 7,500+ people in Bestway Healthcare who are committed to improving the lives of our patients and
customers, thank you all."